A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
Primary Purpose
Neoplasms Malignant
Status
Recruiting
Phase
Phase 1
Locations
Australia
Study Type
Interventional
Intervention
AK112
Sponsored by

About this trial
This is an interventional treatment trial for Neoplasms Malignant focused on measuring anti-PD-1/VEGF bispecific antibody, immunotherapy, immuno-oncology, advanced solid tumors, bispecific, PD-1/VEGF
Eligibility Criteria
Inclusion Criteria:
- Written and signed informed consent and any locally required authorization obtained from the subject/legal representative.
- In dose-escalation cohorts (Phase 1a), histologically or cytologically documented advanced or metastatic solid tumor that is refractory/relapsed to standard therapies, or for which no effective standard therapy is available, or the subject refuses standard therapy.
- In the dose-expansion cohorts (Phase 1b), histologically or cytologically confirmed selected advanced solid tumors.
- Subject must have at least one measurable lesion according to RECIST Version1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
- Available archived tumor tissue sample to allow for correlative biomarker studies. If unavailable or unsuitable, the subject must consent and undergo fresh tumor biopsy.
- Adequate organ function.
- Subjects with central nervous system (CNS) metastases must have been treated, be asymptomatic.
- Females of childbearing potential and non-sterilized males who are sexually active must use an effective method of contraception from screening until 120 days after final dose of investigational product or women of non child bearing potential.
- Life expectancy ≥12 weeks.
Exclusion Criteria:
- History of severe hypersensitivity reactions to other mAbs.
- Prior malignancy active within the previous 3 years except for the tumor for which a subject is enrolled in the study, and locally curable cancers that have been apparently cured, (e.g. basal cell skin cancer, or carcinoma in situ of the cervix or breast).
- For subjects enrolled in the dose escalation phase, having received prior anti-PD-1, anti-PD-L1, anti-CTLA-4 or any other immunotherapy or immune-oncology (IO) agent within 28 days of commencing treatment with AK112 or experienced a toxicity that led to permanent discontinuation of prior immunotherapy. All AEs while receiving prior immunotherapy have not completely resolved or resolved to Grade 1 prior to screening, required the use of additional immunosuppression other than corticosteroids
- Receiving any immunotherapy, conventional or investigational systemic anticancer therapy within 4 weeks prior to the first dose
- Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment (hormones use for non-cancer related conditions is acceptable).
- Subjects with clinically significant cardiovascular disease
- Subjects with a condition requiring systemic treatment with either corticosteroid (> 10 mg daily ) or other immunosuppressive medications within 2 weeks of study drug administration.
- Current or recent use of aspirin (> 325 mg/day) or treatment with dipyramidole, ticlopidine, clopidogrel, and cilostazol.
- Current unstable of full-dose oral or parenteral anticoagulants or thrombolytic agents for > 2 weeks prior to the first dose of AK112
- Active or prior documented autoimmune disease within the past 2 years or conditions not expected to recur in the absence of an external trigger)
- Active or prior documented inflammatory bowel disease
- History of primary immunodeficiency.
- History of organ transplant.
- Known allergy or reaction to any component of the AK112 formulation.
- History of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies.
- Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1
- Major surgical procedure within 30 days prior to the first dose of AK112 or still recovering from prior surgery.
- Known history of HIV.
- Known active hepatitis B or C infections. Note: Subjects with HCC and positive HBsAg result are eligible if the subjects were treated with antiviral therapy and HBV viral load less than 500 IU/mL prior to first dose of AK112.
- An active infection requiring systemic therapy
- Received live attenuated vaccination within 30 days prior to the first dose of AK112.
Sites / Locations
- Border Medical Oncology
- Scientia Clinical Research LtdRecruiting
- Blacktown HospitalRecruiting
- ICON Cancer FoundationRecruiting
- Adelaide Cancer CentreRecruiting
- Monash HealthRecruiting
- Peter MacCallum Cancer CentreRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
AK112
Arm Description
AK112 IV every 2 weeks (q2w) or every 3 weeks (q3w)
Outcomes
Primary Outcome Measures
Incidence and nature of participants with adverse events (AEs)
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Number of participants with DLTs
DLTs will be assessed during the dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle (4 weeks) of treatment.
Secondary Outcome Measures
Objective response rate (ORR)
The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1.
Disease control rate (DCR)
The DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD at 16 and 24 weeks respectively) based on RECIST Version 1.1.
Progression-free survival (PFS)
Progression-free survival is defined as the time from the start of treatment with AK112 until the first documentation of disease progression or death due to any cause, whichever occurs first.
Overall survival (OS)
Overall survival is defined as the time from the start of treatment with AK112 until death due to any cause.
Area under the curve (AUC) of AK112 for assessment of pharmacokinetics
The endpoints for assessment of PK of AK112 include serum concentrations of AK112 at different timepoints after AK112 administration.
Maximum observed concentration (Cmax) and Minimum observed concentration (Cmin) of AK112
The endpoints for assessment of PK of AK112 include serum concentrations of AK112 at different timepoints after AK112 administration.
Number of subjects who develop detectable anti-drug antibodies (ADAs)
The immunogenicity of AK112 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs).
Full Information
NCT ID
NCT04047290
First Posted
August 5, 2019
Last Updated
October 26, 2022
Sponsor
Akesobio Australia Pty Ltd
1. Study Identification
Unique Protocol Identification Number
NCT04047290
Brief Title
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
Official Title
A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects With Advanced Solid Tumors
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 20, 2019 (Actual)
Primary Completion Date
June 30, 2023 (Anticipated)
Study Completion Date
August 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Akesobio Australia Pty Ltd
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumor malignancies. The study consists of a dose escalation phase (Phase 1a) to determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for AK112 as a single agent, and a dose expansion phase (Phase 1b) in subjects with specific tumor types which will characterize treatment of AK112 as a single agent at the MTD or RP2D.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neoplasms Malignant
Keywords
anti-PD-1/VEGF bispecific antibody, immunotherapy, immuno-oncology, advanced solid tumors, bispecific, PD-1/VEGF
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Model Description
Sequential Assignment Initially, a single-subject cohort will be enrolled at the protocol starting dose of AK112 every 2 weeks (Q2W). Dose escalation will proceed to the next main dose level according to the 3+3+3 dose-escalation procedure until the MTD is reached. Dose expansion phase of the study will be initiated at the Sponsor's discretion at the dose level and treatment schedule which was established as the recommended Phase 2 dose (RP2D) in the dose-escalation phase.
Masking
None (Open Label)
Allocation
N/A
Enrollment
151 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
AK112
Arm Type
Experimental
Arm Description
AK112 IV every 2 weeks (q2w) or every 3 weeks (q3w)
Intervention Type
Drug
Intervention Name(s)
AK112
Intervention Description
AK112 is a PD1/VEGF bispecific antibody.
Primary Outcome Measure Information:
Title
Incidence and nature of participants with adverse events (AEs)
Description
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Time Frame
From time ICF is signed until 90 days after last dose of AK112
Title
Number of participants with DLTs
Description
DLTs will be assessed during the dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle (4 weeks) of treatment.
Time Frame
During the first four weeks of treatment with AK112
Secondary Outcome Measure Information:
Title
Objective response rate (ORR)
Description
The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1.
Time Frame
Up to 2 years
Title
Disease control rate (DCR)
Description
The DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD at 16 and 24 weeks respectively) based on RECIST Version 1.1.
Time Frame
Up to 2 years
Title
Progression-free survival (PFS)
Description
Progression-free survival is defined as the time from the start of treatment with AK112 until the first documentation of disease progression or death due to any cause, whichever occurs first.
Time Frame
Up to 2 years
Title
Overall survival (OS)
Description
Overall survival is defined as the time from the start of treatment with AK112 until death due to any cause.
Time Frame
Up to 2 years
Title
Area under the curve (AUC) of AK112 for assessment of pharmacokinetics
Description
The endpoints for assessment of PK of AK112 include serum concentrations of AK112 at different timepoints after AK112 administration.
Time Frame
From first dose of AK112 through 90 days after last dose of AK112
Title
Maximum observed concentration (Cmax) and Minimum observed concentration (Cmin) of AK112
Description
The endpoints for assessment of PK of AK112 include serum concentrations of AK112 at different timepoints after AK112 administration.
Time Frame
From first dose of AK112 through 90 days after last dose of AK112
Title
Number of subjects who develop detectable anti-drug antibodies (ADAs)
Description
The immunogenicity of AK112 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs).
Time Frame
From first dose of AK112 through 90 days after last dose of AK112
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Written and signed informed consent and any locally required authorization obtained from the subject/legal representative.
In dose-escalation cohorts (Phase 1a), histologically or cytologically documented advanced or metastatic solid tumor that is refractory/relapsed to standard therapies, or for which no effective standard therapy is available, or the subject refuses standard therapy.
In the dose-expansion cohorts (Phase 1b), histologically or cytologically confirmed selected advanced solid tumors.
Subject must have at least one measurable lesion according to RECIST Version1.1.
Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
Available archived tumor tissue sample to allow for correlative biomarker studies. If unavailable or unsuitable, the subject must consent and undergo fresh tumor biopsy.
Adequate organ function.
Subjects with central nervous system (CNS) metastases must have been treated, be asymptomatic.
Females of childbearing potential and non-sterilized males who are sexually active must use an effective method of contraception from screening until 120 days after final dose of investigational product or women of non child bearing potential.
Life expectancy ≥12 weeks.
Exclusion Criteria:
History of severe hypersensitivity reactions to other mAbs.
Prior malignancy active within the previous 3 years except for the tumor for which a subject is enrolled in the study, and locally curable cancers that have been apparently cured, (e.g. basal cell skin cancer, or carcinoma in situ of the cervix or breast).
For subjects enrolled in the dose escalation phase, having received prior anti-PD-1, anti-PD-L1, anti-CTLA-4 or any other immunotherapy or immune-oncology (IO) agent within 28 days of commencing treatment with AK112 or experienced a toxicity that led to permanent discontinuation of prior immunotherapy. All AEs while receiving prior immunotherapy have not completely resolved or resolved to Grade 1 prior to screening, required the use of additional immunosuppression other than corticosteroids
Receiving any immunotherapy, conventional or investigational systemic anticancer therapy within 4 weeks prior to the first dose
Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment (hormones use for non-cancer related conditions is acceptable).
Subjects with clinically significant cardiovascular disease
Subjects with a condition requiring systemic treatment with either corticosteroid (> 10 mg daily ) or other immunosuppressive medications within 2 weeks of study drug administration.
Current or recent use of aspirin (> 325 mg/day) or treatment with dipyramidole, ticlopidine, clopidogrel, and cilostazol.
Current unstable of full-dose oral or parenteral anticoagulants or thrombolytic agents for > 2 weeks prior to the first dose of AK112
Active or prior documented autoimmune disease within the past 2 years or conditions not expected to recur in the absence of an external trigger)
Active or prior documented inflammatory bowel disease
History of primary immunodeficiency.
History of organ transplant.
Known allergy or reaction to any component of the AK112 formulation.
History of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies.
Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1
Major surgical procedure within 30 days prior to the first dose of AK112 or still recovering from prior surgery.
Known history of HIV.
Known active hepatitis B or C infections. Note: Subjects with HCC and positive HBsAg result are eligible if the subjects were treated with antiviral therapy and HBV viral load less than 500 IU/mL prior to first dose of AK112.
An active infection requiring systemic therapy
Received live attenuated vaccination within 30 days prior to the first dose of AK112.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Baiyong Li
Phone
+86 (0760) 8987 3999
Email
global.trials@akesobio.com
Facility Information:
Facility Name
Border Medical Oncology
City
Albury
State/Province
New South Wales
Country
Australia
Individual Site Status
Completed
Facility Name
Scientia Clinical Research Ltd
City
Randwick
State/Province
New South Wales
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
Phone
+61 2 9382 5811
First Name & Middle Initial & Last Name & Degree
Charlotte Lemech, MBBS
Facility Name
Blacktown Hospital
City
Sydney
State/Province
New South Wales
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Natalie Byrne
Email
Natalie.Byrne@health.nsw.gov.au
First Name & Middle Initial & Last Name & Degree
Adnan Nagrial, MBBS
Facility Name
ICON Cancer Foundation
City
South Brisbane
State/Province
Queensland
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
Phone
+61 3737 4500
First Name & Middle Initial & Last Name & Degree
Jermaine Coward, MBBS
Facility Name
Adelaide Cancer Centre
City
Kurralta Park
State/Province
South Australia
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
Phone
+61 8 8292 2220
First Name & Middle Initial & Last Name & Degree
Anna Mislang, MBBS
Facility Name
Monash Health
City
Clayton
State/Province
Victoria
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sophia Frentzas, Dr
Phone
+61 3 8572 2429
Email
sophia.frentzas@monashhealth.org
First Name & Middle Initial & Last Name & Degree
Sophia Frentzas, MBBS
Facility Name
Peter MacCallum Cancer Centre
City
Melbourne
State/Province
Victoria
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Linda Mileshkin, MBBS
Phone
+61 3 8559 5000
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
We'll reach out to this number within 24 hrs